Cantex Pharmaceuticals, Inc.

Dec 09, 2024

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

May 28, 2024

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 20, 2024

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER

Feb 22, 2024

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Apr 29, 2020

Chimerix, Exclusive Licensee of Cantex' Lead Product DSTAT, has Announced Initiation of a Phase 2/3 Study of DSTAT, Formerly Known as CX-01, in Acute Lung Injury for Patients with Severe COVID-19